Kite’s Yescarta and Tecartus therapies show promise
Objective response rate and complete response rates were encouraging for both treatments
Read More
Tag: Yescarta
NICE approves expanded use of Yescarta and Tecartus
Kite’s two CAR T-Cell therapies involve treating several different types of blood cancer
Read More
Kite’s Yescarta to receive European marketing authorisation
First treatment in 30 years to improve second-line treatment of DLBCL
Read More
Kite’s CAR T therapy Yescarta shows potential in new indication
ZUMA-12 phase II study is evaluating therapy as a first-line treatment for high-risk large B-cell lymphoma
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Read More
Gilead strikes deal with NHS England on Yescarta access
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.
Read More
NICE says ‘no’ to Gilead’s Yescarta in draft guidelines
NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by the National Institute for Health and Care Excellence.
Read More
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
Read More
CAR-T therapies leap towards EU approval
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Read More
US approves second CAR-T therapy
Gilead’s Yescarta – recently acquired through its purchase of Kite Pharma – has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
